Covid-19 antibody combination (BRII-196 and BRII-198) will not progress into Phase III study

The ACTIV-3 study evaluated the antibody combination in patients hospitalised with Covid-19, relative to a standard of care. Based on analysis of interim data, the Data & Safety Monitoring Board determined that the pre-specified efficacy criteria have not been met.

Biospace Inc.